Andreas Wallnoefer News Today

Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress

Foreign Affairs Provides up to the minute Raw News, reportage, current affairs, Open Source Intelligence, OSI, Information, Analysis, and Essays, all published with immediacy at the time of relevancy

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Biopharma Corteria, which announced an oversubscribed €65M ($71M) Series A co-led by investment firms OrbiMed (US) and Jeito Capital (EU), will be  using the funding to advance its cardiovascular pipeline into the clinic. Click to read more...

Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases

Jeito Capital co-leads EUR 65 million (USD 711M) financing in

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Additions to EyeBio's leadership team include world-class disruptors with deep experience addressing urgent unmet needs in treatment of eye diseases - EyeBio co-founder Anthony P. Adamis, M.D., appointed

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for

CatalYmtoday announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation